Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies.

Literature DB >> 8285641

Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies.

C Lumbreras¹, J R Otero, J A Herrero, R Gomez, M Lizasoain, J M Aguado, F Colina, I Garcia, E Moreno, A R Noriega.

Abstract

The efficacy of ganciclovir, given prophylactically, to prevent cytomegalovirus-related disease was evaluated in liver transplant recipients, mostly seropositive, under treatment with OKT3 monoclonal antibodies. The incidence of cytomegalovirus disease and visceral involvement was reduced, respectively, from 52 and 36% in the control group to 12 and 8% in the ganciclovir-treated patients. Leukopenia was a frequent (32%) side effect of ganciclovir administration.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1993 PMID： 8285641 PMCID： PMC192416 DOI： 10.1128/AAC.37.11.2490

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

17 in total

1. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations.

Authors: C V Paya; P E Hermans; R H Wiesner; J Ludwig; T F Smith; J Rakela; R A Krom
Journal: J Infect Dis Date: 1989-11 Impact factor: 5.226

2. Cytomegalovirus infection in pediatric liver recipients. A virological survey and prophylaxis with CMV immune globulin and early DHPG treatment.

Authors: E Dussaix; C Wood
Journal: Transplantation Date: 1989-08 Impact factor: 4.939

3. The role of CMV immune prophylaxis in patients at risk of primary CMV infection following orthotopic liver transplantation.

Authors: R Bell; A G Sheil; J A McDonald; G W McCaughan
Journal: Transplant Proc Date: 1989-10 Impact factor: 1.066

4. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens.

Authors: C A Gleaves; T F Smith; E A Shuster; G R Pearson
Journal: J Clin Microbiol Date: 1985-02 Impact factor: 5.948

5. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis.

Authors: M T Grattan; C E Moreno-Cabral; V A Starnes; P E Oyer; E B Stinson; N E Shumway
Journal: JAMA Date: 1989 Jun 23-30 Impact factor: 56.272

6. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.

Authors: H H Balfour; B A Chace; J T Stapleton; R L Simmons; D S Fryd
Journal: N Engl J Med Date: 1989-05-25 Impact factor: 91.245

7. Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients.

Authors: R J Stratta; M S Shaefer; K A Cushing; R S Markin; R P Wood; A N Langnas; E C Reed; G L Woods; J P Donovan; T J Pillen
Journal: Transplantation Date: 1991-01 Impact factor: 4.939

8. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies.

Authors: N Singh; J S Dummer; S Kusne; M K Breinig; J A Armstrong; L Makowka; T E Starzl; M Ho
Journal: J Infect Dis Date: 1988-07 Impact factor: 5.226

9. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation.

Authors: J G O'Grady; G J Alexander; S Sutherland; P T Donaldson; F Harvey; B Portmann; R Y Calne; R Williams
Journal: Lancet Date: 1988-08-06 Impact factor: 79.321

10. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.

Authors: T C Merigan; D G Renlund; S Keay; M R Bristow; V Starnes; J B O'Connell; S Resta; D Dunn; P Gamberg; R M Ratkovec
Journal: N Engl J Med Date: 1992-04-30 Impact factor: 91.245

9 in total

Review 1. Infections in solid-organ transplant recipients.

Authors: R Patel; C V Paya
Journal: Clin Microbiol Rev Date: 1997-01 Impact factor: 26.132

Review 2. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors: I G Sia; R Patel
Journal: Clin Microbiol Rev Date: 2000-01 Impact factor: 26.132

3. The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation.

Authors: Giulia Bedino; Pasquale Esposito; Francesca Bosio; Valeria Corradetti; Teresa Valsania; Chiara Rocca; Eleonora Francesca Pattonieri; Marilena Gregorini; Teresa Rampino; Antonio Dal Canton
Journal: Int Urol Nephrol Date: 2012-09-30 Impact factor: 2.370

4. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3.

Authors: J M Aguado; M A Gomez-Sanchez; C Lumbreras; J Delgado; M Lizasoain; J R Otero; J J Rufilanchas; A R Noriega
Journal: Antimicrob Agents Chemother Date: 1995-07 Impact factor: 5.191

Review 5. Viral prophylaxis in organ transplant patients.

Authors: Michelle Slifkin; Shira Doron; David R Snydman
Journal: Drugs Date: 2004 Impact factor: 9.546

Review 6. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.

Authors: Daniel S Owers; Angela C Webster; Giovanni F M Strippoli; Kathy Kable; Elisabeth M Hodson
Journal: Cochrane Database Syst Rev Date: 2013-02-28